Avalo Therapeutics Announces Material Agreements
Ticker: AVTX · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, termination
Related Tickers: AVLO
TL;DR
AVLO entered and terminated material agreements on June 3rd. Big changes coming.
AI Summary
On June 3, 2025, Avalo Therapeutics, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing details these significant corporate actions, which are typically related to business operations, financing, or strategic partnerships. Further specifics on the nature and financial implications of these agreements are expected to be detailed within the full filing.
Why It Matters
This filing indicates significant changes in Avalo Therapeutics' contractual relationships, which could impact its business strategy, financial health, and future operations.
Risk Assessment
Risk Level: medium — The entry into and termination of material definitive agreements can signal significant shifts in a company's strategic direction or financial stability, warranting closer examination.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37590 (identifier) — Commission File Number
- 45-0705648 (identifier) — IRS Employer Identification No.
- 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087 (address) — Principal executive offices
- Cerecor Inc. (company) — Former company name
FAQ
What was the nature of the Material Definitive Agreement entered into by Avalo Therapeutics on June 3, 2025?
The filing states that Avalo Therapeutics, Inc. entered into a Material Definitive Agreement on June 3, 2025. Specific details of this agreement are not provided in the summary but are typically found within the full document.
What was the reason for the termination of a Material Definitive Agreement by Avalo Therapeutics?
The filing indicates that Avalo Therapeutics, Inc. terminated a Material Definitive Agreement on June 3, 2025. The specific reasons for this termination are not detailed in the provided summary.
What is Avalo Therapeutics, Inc.'s principal executive office address?
Avalo Therapeutics, Inc.'s principal executive offices are located at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.
When did Avalo Therapeutics, Inc. change its name from Cerecor Inc.?
Avalo Therapeutics, Inc. was formerly known as Cerecor Inc., with the date of the name change being November 2, 2011.
What is the Commission File Number for Avalo Therapeutics, Inc.?
The Commission File Number for Avalo Therapeutics, Inc. is 001-37590.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Avalo Therapeutics, Inc. (AVTX).